Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage ...

Core Insights - Aclarion, Inc. has announced the publication of a featured article in the Special Pain Issue of the International Journal of Spine Surgery, highlighting the importance of understanding pain as a complex condition and showcasing their Nociscan solution for chronic low back pain [1][2][4] Company Overview - Aclarion is a healthcare technology company focused on leveraging biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][6] - The company’s Nociscan solution is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [2][7] Product Details - Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) data to extract and quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [6][7] - A case study featured in the publication demonstrated Nociscan's effectiveness in identifying the source of pain, leading to successful surgical intervention for a patient [3][4] Industry Context - The Special Pain Issue of IJSS emphasizes the evolving understanding of pain, integrating objective biomarkers with clinical judgment to enhance diagnosis and treatment [2][4] - IJSS is recognized for advancing scientific and clinical excellence in spine care, publishing over 150 articles annually from over 40 nations [4][6]

Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the f ...

MONTREAL and TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) ("Volatus" or "the Company"), a leader in aerial and defense solutions, is pleased to announce the appointment of Lieutenant-General (Ret’d) Christopher J. Coates, CMM, MSM, CD, LOM, to its Board of Advisors. His appointment strengthens the Company’s defense expertise as Volatus advances its vision to support the Canadian Armed Forces (CAF), NORAD modernization, and allied defense ...

Ness Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that it and its majority-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), have entered into definitive agreements with institutional investors (the “Investors”) for an investment in Eye-Net, based on an Eye-Net pre-money valuation of $55 million. The gross proceeds of the investment amounted to $3 million, before d ...

JACKSONVILLE, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Landstar System, Inc. (NASDAQ: LSTR), a technology-enabled, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation logistics services, announced that on December 3, 2025, its Board of Directors declared a special one-time cash dividend in the amount of $2.00 per share, payable on January 21, 2026 to stockholders of record as of the close of business on January 6, 2026. “Landstar’s strong balance ...

| Title: | Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients | | --- | --- | | | Hope for Safer, More Effective Breast Cancer Therapy Combinations | | Date: | Thursday, December 11, 2025 | | Time: | 5 p.m. – 6:30 p.m. CT | | Abstract/Poster: | #801 Poster PS4-10-15 | | Presenting author: | Lewis Bender, M.S. M.A. M.B.A., Intensity Therapeutics | | Title: | Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early Stage Triple Negative Breas ...

SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States. The BalanceTutor is the only known rehabilitati ...

MCLEAN, Va., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. ("Cycurion" or the "Company") (NASDAQ: CYCU), a publicly traded leader in technology and staffing solutions for the public sector, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,657,460 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 3,314,920 shares of common stock at an effective combined price of $3. ...

Core Insights - Polyrizon Ltd. is advancing its development of non-pharmacological solutions for respiratory defense, particularly through its innovative hydrogel-based nasal spray technology [1][4][8] Company Overview - Founded by Tomer Izraeli, Polyrizon focuses on creating smarter nasal protection to address gaps in traditional nasal sprays, which often provide only temporary relief [2][4] - The company's proprietary Capture & Contain™ (C&C) platform utilizes a bio-adhesive hydrogel to form a protective barrier in the nasal cavity, effectively trapping airborne particles [2][4] Product Development - Polyrizon's flagship product, PL-14 Allergy Blocker, is designed to provide drug-free protection against allergens by forming a moisturizing barrier in the nasal cavity [3][4] - The company has achieved significant manufacturing milestones, successfully producing larger-scale batches of PL-14 under controlled conditions, confirming its ability to scale for clinical trials and future commercial production [5][6] Market Potential - The seasonal allergic rhinitis market is projected to grow from USD 11.14 billion in 2025 to USD 13.79 billion by 2032, with a CAGR of 3.1% [4] - The global influenza market is expected to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029, indicating a strong demand for innovative respiratory solutions [4] Future Directions - Polyrizon aims to expand the applications of its C&C platform beyond allergies to include viral protection against respiratory pathogens [7] - The company is also developing its Trap & Target™ (T&T) technology for targeted delivery of active pharmaceutical ingredients, which could address various medical conditions [7][8]